<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599000</url>
  </required_header>
  <id_info>
    <org_study_id>MRAC.09.13</org_study_id>
    <nct_id>NCT01599000</nct_id>
  </id_info>
  <brief_title>Artemether-Lumefantrine Clinical Effectiveness Study</brief_title>
  <official_title>Artemether-Lumefantrine Clinical Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papua New Guinea Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian Agency for International Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Department of Health, Papua New Guinea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Papua New Guinea Institute of Medical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2009, Papua New Guinea officially adopted artemether-lumefantrine (AL) as new national&#xD;
      first-line drug for uncomplicated malaria. The principal purpose of this study is to measure&#xD;
      the absolute effectiveness of AL when used under real-life clinical conditions, as compared&#xD;
      to optimized in-vivo trial conditions. This question was raised by the National Department of&#xD;
      Health in preparation for the country-wide roll-out of AL.&#xD;
&#xD;
      The study is designed as a randomized controlled trial comparing two study arms. Patients in&#xD;
      the &quot;effectiveness arm&quot; receive the first dose of AL under full supervision in the clinic;&#xD;
      the following doses will be taken at home, as in real-life clinical practice and according to&#xD;
      the new national treatment guidelines. Patients in the &quot;efficacy arm&quot; will receive all doses&#xD;
      of AL as directly observed treatment in the clinic in order to establish the efficacy of the&#xD;
      drug when used under ideal conditions.&#xD;
&#xD;
      The study will enroll outpatients aged 6 months to 10 years with a history of fever and a&#xD;
      positive rapid test for malaria. Patients meeting all enrollment criteria and providing full&#xD;
      written informed consent by a parent/caretaker will be randomized into either of the two&#xD;
      study arms. Patients in both arms will be followed up actively for 42 days. Patients in the&#xD;
      efficacy arm will be scheduled for visits on days 0, 1, 2, 3, 7, 14, 28 and 42; patients in&#xD;
      the effectiveness arm on days 0, 3, 7, 14, 28 and 42.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequate Clinical and Parasitological Response (ACPR)</measure>
    <time_frame>42 days</time_frame>
    <description>ACPR = Absence of parasitemia on Day 42 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure (adapted from WHO 2003).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Parasitologically Confirmed; Malarial</condition>
  <arm_group>
    <arm_group_label>Efficacy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effectiveness arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination</intervention_name>
    <description>fixed-dose tablet, six doses over three days, according to weight group</description>
    <arm_group_label>Effectiveness arm</arm_group_label>
    <arm_group_label>Efficacy arm</arm_group_label>
    <other_name>Coartem, Novartis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 months to 10 years (+/- 1 month for children without known date of birth)&#xD;
&#xD;
          -  Permanent resident in the study area&#xD;
&#xD;
          -  Not enrolled in another study at the same time&#xD;
&#xD;
          -  No known history of hypersensitivity reactions to artemether or lumefantrine&#xD;
&#xD;
          -  History of fever in the previous 72 hours (approximate)&#xD;
&#xD;
          -  Rapid diagnostic test (RDT) positive for any species of Plasmodium&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General danger signs: inability to drink or breastfeed, vomiting everything, recent&#xD;
             history of convulsions, lethargy or unconsciousness, inability to sit or stand up&#xD;
&#xD;
          -  Signs of severe malaria (impaired consciousness, respiratory distress, circulatory&#xD;
             collapse, abnormal bleeding, jaundice, or as determined by clinician)&#xD;
&#xD;
          -  Severe malnutrition: defined as a child whose weight-for-height is below -3 standard&#xD;
             deviation or less than 70% of the median of the NCHS/WHO normalized reference values,&#xD;
             or who has symmetrical oedema involving at least the feet; or middle upper arm&#xD;
             circumference under 12 cm&#xD;
&#xD;
          -  Clinically significant concomitant disease requiring admission&#xD;
&#xD;
          -  Contraindications mentioned in the national treatment guidelines&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel W Hetzel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papua New Guinea Institute of Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mueller Ivo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter and Eliza Hall Institute of Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter M Siba, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papua New Guinea Institute of Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gurney Health Centre</name>
      <address>
        <city>Alotau</city>
        <state>Milne Bay</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Papua New Guinea</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>April 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>August 14, 2012</last_update_submitted>
  <last_update_submitted_qc>August 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>Plasmodium</keyword>
  <keyword>Papua New Guinea</keyword>
  <keyword>artemether/lumefantrine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

